This site is intended for healthcare professionals
Blue test tubes arranged in a line, disappearing into the background
  • Home
  • /
  • News
  • /
  • 2014
  • /
  • 01
  • /
  • CHMP recommends approval of Latuda for Schizophren...
Drug news

CHMP recommends approval of Latuda for Schizophrenia - Takeda

Read time: 1 mins
Last updated:26th Jan 2014
Published:26th Jan 2014
Source: Pharmawand
"

The EMA's CHMP has issued a Positive Opinion for Latuda (lurasidone), from Dainippon Sumitomo Pharma and Takeda, for the treatment of Schizophrenia in adults. The Positive CHMP Opinion was based on a comprehensive clinical trial program which included placebo and active comparators.

Lurasidone was shown to be effective in treating both positive and negative symptoms in acutely psychotic patients with Schizophrenia over 6 weeks. In short and longer term clinical studies, lurasidone has demonstrated effectiveness with low rates of metabolic change. Lurasidone was generally well-tolerated and had low rates of weight increase, as well as lipid and glucose disturbance, in the treatment of patients with schizophrenia.

How do you prefer to access medical updates and information?

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.